TransMedics Group, Inc. (TMDX) Stock Price: $78.79+5.57 (+7.61%)
At close: Jun 18, 2026, 4:00 PM ET
The closing share price for TransMedics Group, Inc. (TMDX) stock was $78.79 for Thursday, June 18, 2026, up 7.61% on the day.
Longer view (total return, dividends reinvested): past 12 months -36.5% · 3-year avg +0.1%/yr · 5-year avg +21.5%/yr
TMDX Price Chart
TMDX is featured in
TMDX Key Metrics
See All MetricsLAST CLOSE PRICE
$78.79
52-WEEK RANGE
$60.10 - $156.00
BETA
1.88
% FROM 52W HIGH
-49.49%
MARKET CAP
$2.72B
DIVIDEND YIELD
N/A
PE RATIO
trailing TTM
18.03
PE RATIO (FWD)
next-FY estimate
38.89
P/B RATIO
5.77
DEBT / EQUITY
0.99
REVENUE TTM
$635.89M
NET INCOME TTM
$171.92M
NET PROFIT MARGIN TTM
27.04%
TTM TOTAL RETURN
-36.48%
3Y TOTAL RETURN
+0.07%
5Y TOTAL RETURN
+21.48%
TMDX Earnings Preview
Next Earnings Date
Jul 30, 2026
40 days away
EPS Estimate
0.53
Revenue Est.
$184.69M
Last Quarter Results
EPS
$0.30
vs Estimate
$0.61
Revenue
$173.93M
vs Estimate
$174.44M
TMDX Analyst Ratings
Consensus Rating
Based on 9 analysts
Average Price Target
$117.33
+48.9% upside
Low
$80.00
Current
$78.79
High
$142.00
TMDX Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $0.73 | $0.76 | $0.80 | 2 |
| Q2 2027 | $0.84 | $0.88 | $0.92 | 2 |
| Q3 2027 | $0.75 | $0.78 | $0.82 | 2 |
| Q4 2027 | $0.90 | $0.93 | $0.98 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.63 | $2.03 | $2.26 | 6 |
| FY 2027 | $2.83 | $3.56 | $4.66 | 6 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $201.01M | $207.24M | $215.12M | 4 |
| Q2 2027 | $210.18M | $216.69M | $224.93M | 3 |
| Q3 2027 | $201.52M | $207.77M | $215.67M | 3 |
| Q4 2027 | $221.70M | $228.57M | $237.26M | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $729.41M | $733.27M | $739.67M | 9 |
| FY 2027 | $864.46M | $872.11M | $887.33M | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareTMDX Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TMDX | $2.72B | $78.79 | +7.61% | -36.48% | +21.48% | N/A | — |
| 2XRAY | $2.07B | $10.33 | +2.99% | -30.45% | -28.87% | -15.36% | vs TMDX |
| 3ME | $15.31M | $0.61 | +0.00% | -67.07% | -68.93% | N/A | vs TMDX |
| 4BIO | $7.64B | $282.44 | -0.78% | +21.76% | -14.63% | +7.20% | vs TMDX |
| 5HIMS | $7.91B | $35.47 | +11.23% | -41.94% | +26.16% | N/A | vs TMDX |
| 6TEM | $8.87B | $50.84 | +4.20% | -26.44% | N/A | N/A | vs TMDX |
TMDX Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein